

Successful Treatment of Pulmonary Mucormycosis Caused by *Rhizopus Microsporus* With Posaconazole

Fan Yuan

Southeast University Medical College

Jun Chen

Nanjing Jinling Hospital: East Region Military Command General Hospital

Fang Liu

Nanjing Jinling Hospital: East Region Military Command General Hospital

Yongchao Dang

Nanjing Jinling Hospital: East Region Military Command General Hospital

Qingtao Kong

Nanjing Jinling Hospital: East Region Military Command General Hospital

Hong Sang (✉ sanghong@nju.edu.cn)

Nanjing Jinling Hospital: East Region Military Command General Hospital

Case report

Keywords: pulmonary mucormycosis, *Rhizopus microspores*, diabetes mellitus, posaconazole

Posted Date: March 16th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-302265/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at European Journal of Medical Research on November 14th, 2021. See the published version at <https://doi.org/10.1186/s40001-021-00602-x>.

Abstract

Background: Mucormycosis is a rare fungal infection occurring chiefly in the lung or the rhino-orbital-cerebral compartment, particularly in patients with immunodeficiency or diabetes mellitus. Among *Mucorales* fungi, *Rhizopus* spp. are the most common cause of mucormycosis.

Case presentation: We report the case of pulmonary mucormycosis caused by *Rhizopus microsporus* in a young patient with diabetes but no other apparent risk factors. The diagnosis has mainly relied on clinical manifestation, positive pulmonary tissue biopsy, and fungal culture. The patient was successfully treated with posaconazole oral suspension and remains asymptomatic at one-year follow-up.

Conclusions: Pulmonary mucormycosis is a life-threatening condition and based on direct microscopy, histopathology, and culture for the diagnosis.

Background

Mucormycosis is a rare opportunistic infection but is associated with high mortality and morbidity. Mucormycosis occurs most commonly in immunocompromised patients, such as those with poorly controlled diabetes mellitus, solid organ or hematopoietic stem cell transplantation, trauma, and those receiving immunosuppressive therapy [1–3]. The most common site of infection was rhino-orbital-cerebral, followed by pulmonary. Pulmonary mucormycosis (PM) is a life-threatening condition if delay in diagnosis and treatment. A retrospective review found that, in zygomycosis, the mortality for diabetes was 44%, whereas PM mortality increased to 76% [4]. Here, we present a case of PM caused by *Rhizopus microsporus* in a patient with diabetes mellitus.

Case Presentation

A 26-year-old male carpenter was presented to our hospital with low-grade fever, cough, expectoration, and stethalgia for one month. Several days later, his symptoms were aggravating then he was initially admitted to a local hospital where he was diagnosed with pneumonia and empirically treated with cephalosporins. On laboratory investigations, total white blood cell count (WBC) was $17.19 \times 10^9/L$ with 74.1% neutrophil. Serial chest X-rays showed pneumonia in the right upper and lower lobe of lung and left lower lobe of lung. Computed tomography (CT) of the chest demonstrated inflammation of both lungs.

Four days later, antibiotic therapy was changed to vancomycin and sulperazone due to sputum culture reported the growth of *gram-positive cocci*. A week after the treatment changed, a reexamination of thoracic CT showed patchy consolidation in both lungs with pulmonary cavitation formation (Fig. 1a). Therefore, he came to our hospital for further treatment. The patient had a two-year history of type 2 diabetes and no history of hypertension, coronary heart disease, tuberculosis, chronic obstructive pulmonary disease, or chronic bronchitis. He did not take oral anti-diabetic drugs regularly and did not monitor blood glucose.

His glycated hemoglobin (HbA1c) was 12.3%, creatinine and blood urea nitrogen were normal. Furthermore, the third thoracic CT shows a trend of gradual progress. Bronchoscopy revealed sticky purulent secretions in the left and right main bronchus, in each segment bronchus, especially in the left upper anterior lobe, the left lingual lobe, the left medial basal segment of the lower lobe, and the left dorsal segment of the lower lobe. The outcome of Ziehl-Neelsen staining was negative. Histopathology showed the disappearance of the alveolar structure, fibroplasia, and necrosis. Periodic acid-Schiff (PAS) staining of the tissue presented broad, thin-walled, and aseptate fungal hyphae as well as right-angled hyphal branches (Fig. 2a). The samples were inoculated on Sabouraud dextrose agar (SDA) media under 30°C and white colonies appeared after five days. The fungus was then subcultured on Potato Dextrose Agar (PDA) plates. Light microscope examination showed that nodal rhizoids branched a pair of brownish sporangiophores and sporangiospores were hyaline, angular, and broadly ellipsoidal (Fig. 2b).

For further identification, the ITS regions were sequenced with primer ITS1 and primer ITS4. The sequence of the isolate aligned with 99 % similarity to multiple sequences (e.g., accession number KM103772.1) of *Rhizopus microsporus* available in GenBank database. Temperature tests revealed that the isolate grew well at 37°C, 40°C and 45°C, but did not grow at 50°C. Antifungal susceptibility was performed in accordance with the CLSI M38-A guidelines [5].

The samples were inoculated on SDA media The isolate was sensitive to posaconazole and amphotericin B, with resistance to fluconazole and itraconazole. Taken the drug antifungal susceptibility into consideration, the patient was supervised to the following regimen: posaconazole oral suspension (10mL twice a day), ambroxol (30mg, three times a day), repaglinide (1mg, three times a day) combined with low-sugar, high-fiber diets. After approximately 6 months of treatment with posaconazole oral suspension, the patient was well and asymptomatic, and the lesions completely resolved (Fig. 1b).

Discussion And Conclusion

PM is an uncommon presentation in diabetic patients but is associated with high mortality and morbidity. An early diagnosis of PM is difficult, due to the rarity of the disease and clinical and radiological features resembling tuberculosis (TB).

Upon suspicion of mucormycosis, European Confederation of Medical Mycology (ECMM) strongly recommended appropriate imaging to document the extent of disease and an early complete surgical treatment whenever possible, in addition to systemic antifungal therapy [6]. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, followed by intravenous isavuconazole and intravenous or delayed-release tablet posaconazole. A study of patients with hematological diseases showed that posaconazole oral suspension is effective as a salvage therapy for invasive fungal infections [7]. Both triazoles are strongly recommended in salvage treatments. Amphotericin B deoxycholate is not recommended, because of substantial toxicity, except the only option in resource-limited conditions. Due to nonspecific clinical presentation, a clinician must keep a high index of suspicion in mind especially in diabetic patients, and pursue invasive testing early to establish a prompt

diagnosis. ECMM clinical guidelines strongly recommend direct microscopy, histopathology, and culture for the diagnosis [6].

The current case is a 26-year-old immunocompetent patient whose work as a carpenter exposes him to a wide range of fungal spores. A study showed that airborne spores of *Rhizopus microsporus* were frequently found in filter samples of wood trimmers [8]. Consequently, work-related direct inhalation of the *Rhizopus microsporus* was most probably the cause of the pulmonary infection. A retrospective cohort study showed that the incidence of breakthrough invasive fungal infections was not significantly different between patients receiving the tablet formulation and those receiving the oral suspension formulation among patients with hematologic malignancies [9]. After comprehensive consideration, our patient has been treated with posaconazole oral suspension and repaglinide. Surgical opinion was sought but was not advisable due to bilateral lung involvement. After approximately 6 months of treatment with posaconazole oral suspension, the patient was well and asymptomatic, and the lesions improved obviously on thoracic CT.

In conclusion, we have described a rare case of pulmonary infection caused by *Rhizopus microsporus* in a patient in the absence of any other immunodeficiency disease except diabetes. The observations in our case emphasize the importance of considering fungal infections in patients with common diseases, such as untreated diabetes mellitus, and with long term occupational exposure history. Furthermore, effective health education programs should be implemented to improve the awareness of workers such as carpenter, air-conditioning technician, and cleaner to decrease the burden of such serious environment-related infections.

Abbreviations

PM: Pulmonary mucormycosis; WBC: blood cell count; CT: Computed tomography; PAS: Periodic acid-Schiff; SDA: Sabouraud dextrose agar; PDA: Potato Dextrose Agar; TB: tuberculosis; ECMM: European Confederation of Medical Mycology

Declarations

Ethics approval and consent to participate

Not applicable.

Consent to publish

Written consent has been obtained from the patient for publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Funding

The author received no funding for this work.

Authors' Contributions

YF, CJ, LF, DY, KQ and SH acquired and interpreted the data, drafted and revised the manuscript, and reviewed and approved the final version of the manuscript.

Availability of data and materials

Not applicable

Acknowledgements

The authors gratefully acknowledge the patient profiled in this report for formally permitting us to report details relating to his case.

References

1. Corzo-León DE, Chora-Hernández LD, Walsh TJ, et al. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. *Med Mycol.* 2018 Jan 01 ;56(1):29-43; <https://doi.org/10.1093/mmy/myx017>
2. Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. *Emerg Infect Dis.* 2014; 20: 1149–1155; <https://doi.org/10.3201/eid2007.140087>
3. Lelievre L, Garcia-Hermoso D, French Mycosis Study Group, et al. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. *Medicine (Baltimore).* 2014 Nov ;93(24):395-404; <https://doi.org/10.1097/MD.0000000000000221>
4. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis* 2005;41:634-53; <https://doi.org/10.1086/432579>
5. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. Clinical and Laboratory Standards Institute, Villanova, Pa.
6. Cornely OA, Alastruey-Izquierdo A, Mucormycosis ECMM MSG Global Guideline Writing Group, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *Lancet Infect Dis.* 2019 12;19(12):e405-e421; [https://doi.org/10.1016/S1473-3099\(19\)30312-3](https://doi.org/10.1016/S1473-3099(19)30312-3)
7. Zhang S, Zhang P, Feng S, et al. Posaconazole oral suspension as salvage therapy for invasive fungal disease in patients with hematological diseases. *Future Microbiol.* 2019 04;14:477-488; <https://doi.org/10.2217/fmb-2018-0344>

8. Eduard W, Sandven P, Levy F. Relationships between exposure to spores from *Rhizopus microsporus* and *paecilomyces variotii* and serum IgG antibodies in wood trimmers. *Int Arch Allergy Imm.*1992,97(4):274-282; <https://doi.org/10.1159/000236133>
9. Furuno JP, Tallman GB, McGregor JC, et al. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections. *Antimicrob Agents Chemother.*2018 10 ;62(10) ; <https://doi.org/10.1128/AAC.00893-18>

Figures




Figure 1

(a) Axial image from CT of the chest demonstrating bilateral patchy consolidation with pulmonary cavitation formation. (b) A follow-up CT scan after six months of antifungal treatment indicated the lesions nearly resolved.




Figure 2

(a) Periodic acid-Schiff (PAS) stain presented broad, thin-walled, ribbon-like, aseptate fungal hyphae and right-angled hyphal branches. And the tissue was infiltrated with numerous lymphocytes (PAS×400).
(b) Light microscope examination showed that brownish sporangiophores were in pairs branching from nodal rhizoids (×400).